Modern oncology has achieved significant success in describing the molecular mechanisms of uncontrolled cellular growth. However, the dominant paradigm still treats cancer primarily as a problem of acceleration, hyperactivation, and excessive signaling stimulation. This work proposes an alternative conceptual framework in which the core of oncogenesis is not so much the amplification of growth signals as the systemic loss of a cell’s ability to perceive and execute stop signals (STOP signals). We consider cancer as a state of acquired STOP resistance and discuss the implications of this view for the interpretation of remission and the prospects of therapeutic strategies.
1. Introduction: an asymmetry of attention
Over the past decades, the cell biology of growth and division has been studied in great detail. Oncogenes, growth factors, proliferative signaling cascades, metabolic shifts—all of these form a dense and well-mapped landscape.
At the same time, systems of biological stopping—signals that terminate division, induce differentiation, drive cell-cycle exit, or establish quiescence—remain conceptually secondary. They are more often treated as a passive absence of growth stimulation rather than as an active, autonomous, and fundamentally important function of living systems.
This asymmetry of attention creates a blind spot: if growth is the “gas pedal,” then where is the brake, and what happens when it fails?
2. The STOP signal as a fundamental function
In normal biology, the STOP signal is not a negation of growth but an independent regulatory loop. It operates at multiple levels:
- cell-cycle exit,
- terminal differentiation,
- contact inhibition,
- programmed apoptosis,
- long-term quiescence.
It is important to emphasize: the STOP signal is not an event, but a state. It requires:
- reception,
- interpretation,
- execution.
Thus, the ability of a cell to stop is an active competence, not a default condition of “no stimulation.”
3. Oncogenesis as acquired STOP resistance
From this perspective, the core of oncogenesis is the acquisition of STOP resistance. A cancer cell may retain superficial sensitivity to individual molecular interventions while losing the ability to enter a stable state of arrest. The STOP signal is either not recognized, interpreted as noise, or blocked at the level of execution. In this model, oncogenes amplify growth, but the key defect is that the brake no longer works.
This helps explain why tumor cells may temporarily respond to therapy and enter partial regression, only to resume growth later without requiring new mutations. STOP resistance is not a point defect but a systemic property.
4. Remission as partial restoration of STOP function
Remission is traditionally interpreted as the result of successful elimination of tumor cells. However, clinical observations point to a more complex picture:
- a tumor may shrink without complete elimination,
- disease may remain stable for long periods,
- in some cases, remission occurs with minimal intervention.
Within the STOP model, remission can be interpreted as a state of partial restoration of STOP function—not a full return to normality, but a transition into a regime of limited, controlled activity. From this viewpoint, the depth and durability of remission correlate with the degree of progressive loss of STOP resistance, rather than solely with the number of destroyed cells. This opens a fundamentally different interpretation of so-called “spontaneous” and unstable remissions.
5. The limits of the elimination paradigm
Contemporary therapy is largely focused on destroying tumor cells:
- surgery,
- chemotherapy,
- radiation,
- targeted drugs.
Within the logic of the STOP model, this strategy addresses the task of “reducing the enemy army” but ignores the task of “disarmament and reintegration.” If a cell remains STOP-resistant, even a minimally surviving population can restore growth. Moreover, selective pressure may favor precisely those clones in which resistance to stopping is most pronounced. This is not an argument against elimination per se, but an indication of its conceptual incompleteness.
6. STOP as a therapeutic goal
If we accept that the key defect is the loss of the ability to stop, a logical but uncomfortable question arises: can the induction of a STOP state be considered an independent therapeutic goal? This is not about a full “return to normal.” Rather, it is about shifting the system into a manageable, stable, non-escalating state. Such an approach does not exclude elimination, but complements it with a fundamentally new vector.
Conclusion: a challenge
It is time to search not only for smarter bullets, but also for the language in which we can tell a cell: “Stop.” This poses a fundamental question: is the induction of a STOP status an achievable therapeutic goal, equal in significance to elimination? Answering this requires recognizing cancer not only as an error of growth, but as a deep disruption of the very logic of biological stopping.
We do not propose ready-made solutions. We propose a point of assembly for a new conversation—and we are open to dialogue with those willing to step beyond the familiar paradigm.